← Back to all trials
Completed
NCT07349459
Cardioprotective Effect of Melatonin Versus Vitamin D in Breast Cancer Patients Receiving Doxorubicin
Conditions: Melatonin, Breast Cancer Patients Diagnosed, Vitamin D Concentration, Doxorubicin
Sex: Female
Ages: 18 Years – 65 Years
Healthy volunteers: No
Phase: NA
Enrollment: 90
Sponsor: Tanta University
Location: Tanta University Tanta
Summary
This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.
Eligibility Criteria
Inclusion Criteria:
* Age from 18 to 65 years old.
* Gender: female.
* Positive breast cancer women who are scheduled to receive Doxorubicin.
* Have a good performance status according to the eastern cooperative oncology group with a score of 0-2.
* Normal baseline Echocardiography with left ventricular ejection fraction ≥ 50%.
* Normal renal and liver function tests.
Exclusion Criteria:
* Pregnant or breastfeeding women.
* Women with HER-2 positive of breast cancer.
* Formerly treated with Doxorubicin.
* Patients with a known hypersensitivity to any of the used drugs.
* On other concomitant vitamins or food supplements.
* Valvular heart disease, coronary artery disease, history of congestive heart failure or cardiomyopathy.
* Impaired Left ventricular systolic function in which the Left Ventricular Ejection Fraction \< 50%.
Source: ClinicalTrials.gov (NCT07349459). StuddyBuddy aggregates publicly available trial information.
